Bradycardic therapy improves left ventricular function and remodeling in dogs with coronary embolization-induced chronic heart failure

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 469-476

  Cheng, Yanping ^a,b   George, Isaac ^b   Yi, Geng Hua ^b   Reiken, Steven ^b   Gu, Anguo ^b   Tao, Yuankai Kenny ^b   Muraskin, Jordan ^b   Qin, Siyi ^b   He, Kun Lun ^b,c   Hay, Ilan ^b   Yu, Kenward ^b   Oz, Mehmet C ^b   Burkhoff, Daniel ^b   Holmes, Jeffrey ^e   Wang, Jie ^a,b,d,f  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d Jack H Skirball Center for Cardiovascular Research   (United States)

^e Columbia University ^*  (United States)

^f CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 [2 (3,4 DIMETHOXYPHENYL)ETHYL] 3 PIPERIDINYLMETHYL] 1,3,4,5 TETRAHYDRO 7,8 DIMETHOXY 2H 3 BENZAZEPIN 2 ONE; ADENOSINE TRIPHOSPHATASE (CALCIUM); CYCLIC AMP DEPENDENT PROTEIN KINASE; METOPROLOL; RYANODINE RECEPTOR 2; SODIUM CALCIUM EXCHANGE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CATHETER; ARTICLE; ARTIFICIAL EMBOLISM; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CONTROLLED STUDY; DOG; DRUG DOSE COMPARISON; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM; SINUS NODE; WESTERN BLOTTING;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZAZEPINES; CALCIUM; CORONARY STENOSIS; DOGS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; MALE; METOPROLOL; PIPERIDINES; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-CALCIUM EXCHANGER; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 34247282122     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118109     Document Type: Article

References (28)

1. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators, La Rovere MT, Bigger JT, Marcus FI, Mrotara A, and Schwartz PJ (1998) Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 351:478-484.
2. Bristow MR (1984) The adrenergic nervous system in heart failure. N Engl J Med 311:850-851.
3. CIBIS II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS II). Lancet 353:9-13.
4. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, et al. (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure: U.S. Carvedilol Heart Failure Study Group. Circulation 94:2800-2806.
5. Frishman WH, Pepine CJ, Weiss RJ, and BaikerWM(1995) Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Am Coll Cardiol 26:305-312.
6. Glasser SP, Michie DD, Thadani U, and Baiker WM (1997) Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Am J Cardiol 79:1401-1405.
7. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, and Bristow MR (1999) Cellular ad molecular remodeling in a heart failure model treated with the β-blocker carteolol. Am J Physiol 45:H1678-H1690.
8. Gwathmey JKL, Copelas R, MacKinnon R, Shoer FJ, Feldman MD, Grossman W, and Morgan JP (1987) Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61:70-76.
9. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99:641-648.
10. He KL, Yi GH, Sherman W, Zhou H, Li Q, Zhang GP, Gu A, Kao R, Haimes H, Harvey J, et al. (2005) Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs. J Heart Lung Transplant 24:1940-1949.
11. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, and Fowler MB (1989) Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79:483-490.
12. Houser SR, Piacentino V III, and Weisser J (2000) Abnormalities of calcium cyclings in the hypertrophied and failing heart. J Mol Cell Cardiol 32:1595-1607.
13. Hu K, Naumann A, Fraccarollo D, Gaudron P, Kaden JJ, Neubauer S, and Ertl G (2003) Heart rate reduction by zaterbradine reduces infarct size and mortality but promotes remodeling in rats with experimental myocardial infarction. Am J Physiol 286:1281-1288.
14. Knecht M, Burkhoff D, Yi GY, Popilskis S, Homma S, Packer M, and Wang J (1997) Coronary endothelial dysfunction precedes heart failure and reduction of coronary reserve in awake dogs. J Mol Cell Cardiol 29:217-227.
15. Kruger C, Landerer V, Zugck C, Ehmke H, Kubler W, and Haas M (2000) The bradycardic agent zatebradine enhances baroreflex sensitivity and heart rate variability in rats early after myocardial infarction. Cardiovasc Res 45:900-912.
16. Lechat PP (2003) Beta-blocker efficacy according to heart rate and rhythm in patients with heart failure: Commentary on the Cardiac Insufficiency Bisoprolol Study II analysis. Cardiac Electrophys Rev 7:233-235.
17. Marx SO, Reiken S, Hisamatsu T, Jayaraman T, Burkhoff D, Rosemblit N, and Marks AR (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365-376.
18. Nagatsu M, Spinale FG, Koide M, Tagawa H, DeFreitas G, Cooper IVG, and Carabello BA (2000) Bradycardia and the role of β-blockade in the amelioration of left ventricular dysfunction. Circulation 101:653-659.
19. Noble D (1984) The surprising heart: a review of recent progress in cardiac electrophysiology. J Physiol 353:1-50.
20. Osculati G, Grassi G, Giannattasio C, Seravalle G, Valagussa F, Zanchetti A, and Mancia G (1990) Early alterations of the baroreceptor control of heart rate in patients with acute myocardial infarction. Circulation 81:939-948.
21. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, Gallagher JJ, and German LD (1986) Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 57:563-570.
22. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, and Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355.
23. Reiken S, Gaburjakova M, Gaburjakova J, He KL, Preito A, Becker E, Yi GY, Wang J, Burkhoff D, and Marks AR (2001) β-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104:2843-2848.
24. Reiken S, Wehrens XH, and Vest JA (2003) Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107:2459-2466.
25. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, and Goldstein S (1994) Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilatation in dogs with reduced ejection fraction. Circulation 89:2852-2859.
26. Schmitze-Spanke S, Granetzny A, Stoffels B, Pomblum VJ, Gams E, and Schipke JD (2004) Effects of a bradycardic agent on postischemic cardiac recovery in rabbits. J Phys Pharm 55:705-712.
27. Steiber J, Wieland K, Stockl G, Ludwig A, and Hofmann H (2006) Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharm 69:1328-1337.
28. Van Bogaert PP and Pittoors F (2003) Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine. Eur J Pharmacol 478:161-171.